Skip Navigation

SPECIAL SECTION: MONOCLONAL ANTIBODIES

WHERE TO GET IN VITRO MABs: ACADEMIC CORE CENTERS AND COMMERCIAL FACILITIES

The amount of MAB needed varies with the intended use. Most research projects and many analytic purposes require only small amounts of a MAB (< 0.1 g). Larger quantities are necessary for routine diagnostic procedures and for therapeutic purposes. Commercial biotechnology companies now handle most of the large-scale production, typically using in vitro methods. Small-scale production in individual research labs accounts for most use of the ascites method these days.

Core centers, located at academic institutions, offer a good alternative for researchers needing small MAB amounts. These are not-for-profit, centralized facilities that offer specialized laboratory services to investigators on a fee-for-service basis. Many are at least partially funded by the National Institutes of Health. Using a core laboratory can provide a more cost-effective way for many investigators to use MABs produced by in vitro methods.

The listings below provide contact information for suppliers of in vitro monoclonal antibodies, including both commercial companies and core laboratories. There may be some overlap among the various lists.

ARDF Resource List of In Vitro MAB Producers.

Johns Hopkins Genetic Resources Core Facility Cell Center

CAAT list of Core Facilities, with contact information.

Small-scale monoclonal antibody production in vitro: Methods and resources. L. Jackson, L. Trudel, and N. Lipman. In: Proceedings of the Production of Monoclonal Antibodies Workshop. Aug. 1999. Edited by J. E. McArdle and C J. Lund. Alternatives Research and Development Foundation.

University of California Center for Animal Alternatives (UCCAA) web site. MABs section: Companies and Core Facilities.

AWIC Information Resources for Adjuvant and Antibody Production: Comparisons and Alternative Technologies (1990-97): Companies and Institutes.

Antibody Resource Page

The Nature Biotechnology Directory

Core laboratories: What is their cost-effectiveness and what are their needs? Margaret Penno. In: CAAT Technical Report #8: Alternatives in Monoclonal Antibody Production. Sept. 1997.

 

New ALTEX: 2/2018

ALTEX cover 51
 

Support ALTWEB, Make a Gift
Online Humane Science Course

MeetingS

 
Building a Better Epithelium: New Frontiers in 3D Conference
April 25, 2019
Cambridge, MA

CellTox 2019
May 7, 2019
Milano, Italy

Biosystems Engineering: Bioreactors and Cell Factories
May 12-17, 2019
Braunweld, Switzerland

ALTERTOX Academy Training:
In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhalation Toxicology
May 23-24, 2019
Neuchatel, Switzerland

6th Symposium on Social Housing of Laboratory Animals
June 3-4, 2019
Beltsville, Maryland

Society for In Vitro Biology Annual Meeting
June 8-12, 2019
Tampa, Florida

Upcoming: CAAT-Europe Information Day On Biology-inspired Microphysiological Systems (MPS) to Advance Medicines for Patients' Benefit
June 17, 2019
Berlin, Germany

ALTERTOX Academy Training:
PBPK Modeling and Quantitative In Vitro-In Vivo Extrapolation
October 3-4, 2019
Wageningen, Netherlands

ALTERTOX Academy Training:
Novel In Silico Models for Assessment of Cosmetics
October 17-18, 2019
Milan, Italy

ALTERTOX Academy Training:
In Vitro Lung Models
November 14-15, 2019
Geneva, Switzerland

Save the Date!
5th International Conference on Alternatives for Developmental Neurotoxicity (DNT) Testing
February 3-5, 2020
Konstanz, Germany

Full Listing of CAAT Programs
and Activities